Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02279862
Title Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy Naive
Recruitment Completed
Gender male
Phase Phase II
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications

prostate cancer

Therapies

Ipilimumab

Age Groups: adult
Covered Countries USA | ITA | FRA | ESP | DEU


No variant requirements are available.